286930-03-8

286930-03-8 structure

Name: Fesoterodine Fumarate
Chemical Name: (E)-but-2-enedioic acid,[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
CAS Number: 286930-03-8
Molecular Formula: C₃₀H₄₁NO₇
Molecular Weight: 527.649
Catalog: Biochemical Inhibitor Neuronal Signaling AChR antagonist
Create Date: 2018-07-12 03:51:53
Modify Date: 2025-08-25 17:02:10
Fesoterodine Fumarate is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist.IC50 value:Target: mAChRFesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.

Name	(E)-but-2-enedioic acid,[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
Synonyms	(R)-Fesoterodine fumarate Fesoterodine Fumarate UNII-EOS72165S7 SPM 8272 SPM 907 Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester, (2E)-2-butenedioate (1:1) Toviaz,Fesoterodine fumarate 2-[(1R)-3-(Diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate (2E)-2-butenedioate (1:1) Propanoic acid,2-methyl-,2-((1R)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester,(2E)-2-butenedioate (1:1) (salt) Fesoterodinefumarate Toviaz (R)-2-(3-(Diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl isobutyrate fumarate Fesoterodine (fumarate)

Description	Fesoterodine Fumarate is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist.IC50 value:Target: mAChRFesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> mAChR Signaling Pathways >> Neuronal Signaling >> mAChR Research Areas >> Neurological Disease
References	[1]. Staskin David; Khullar Vik; Michel Martin C et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourology and urodynamics (2011), 30(8), 1480-5. [2]. Vella Maria; Cardozo Linda Review of fesoterodine. Expert opinion on drug safety (2011), 10(5), 805-8. [3]. Malhotra Bimal; Alvey Christine; Gong Jason et al. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. British journal of clinical pharmacology (2011), 72(2), 257-62. [4]. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96. [5]. Fesoterodine

Boiling Point	518.9ºC at 760 mmHg
Melting Point	72-78ºC
Molecular Formula	C₃₀H₄₁NO₇
Molecular Weight	527.649
Flash Point	267.6ºC
Exact Mass	527.288330
PSA	124.37000
LogP	5.09290
Storage condition	Hygroscopic, Store under Inert atmosphere -20°C Freezer